Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
68 hedge funds and large institutions have $28M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 10 closing their positions.
105% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $512K
31% more capital invested
Capital invested by funds: $21.3M → $28M (+$6.69M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
5% more funds holding
Funds holding: 65 → 68 (+3)
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$743K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$114K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$106K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$106K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$979K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$838K |
| 3 |
Millennium Management
New York
|
-$684K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$476K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$472K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
76
Penserra Capital Management
Orinda,
California
| – | -$233K | -89 | Closed |
|
|
HF
77
HRT Financial
New York
| – | -$59K | -23 | Closed |
|
78
Jane Street
New York
| – | -$17K | -6 | Closed |
|
79
Balyasny Asset Management
Chicago,
Illinois
| – | -$13K | -5 | Closed |
|
|
SG
80
StoneX Group
New York
| – | -$10.2K | -4 | Closed |
|
|
YIH
81
Y-Intercept (HK)
Hong Kong
| – | -$11K | -4 | Closed |
|
|
FCI
82
Financial Counselors Inc
Overland Park,
Kansas
| – | -$7K | -3 | Closed |
|
83
Legal & General Group
London,
United Kingdom
| – | -$5K | -2 | Closed |
|
|
TRCT
84
Tower Research Capital (TRC)
New York
| – | -$7.87K | -2 | Closed |
|
85
Citigroup
New York
| – | -$1K | – | – |
|
86
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | – | – |
|
SEEL Hedge Fund Activity: Q3 2022 in Review
68 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2022, worth a combined $28M — up 31% from $21.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SEEL positions and 10 closed out — a net gain of 3 holders — while 11 added to existing stakes and 18 trimmed.
The largest buyer was MAI Capital Management, adding an estimated $743K. The largest seller was Renaissance Technologies, cutting an estimated $979K.
- 68 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2022, up from 65 in Q2 2022.
- Funds reported $28M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2022, up 31% quarter-over-quarter.
- 13 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of +3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2022 was MAI Capital Management, an estimated $743K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $979K sold.
Based on aggregated 13F filings for Q3 2022.